New drug duo takes aim at hard-to-treat stomach cancer with liver metastases

NCT ID NCT07677293

Not yet recruiting Disease control Sponsor: Peking University Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This phase 3 trial compares a new drug called Retlirafusp alfa plus chemotherapy against standard immunotherapy plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has spread to the liver and has not been treated before. The study aims to see if the new combination helps people live longer without their cancer growing. About 332 participants will be randomly assigned to one of the two treatment groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Retlirafusp alfa
What this could lead to: If successful, this could offer a new first-line treatment option for people with advanced gastric cancer that has spread to the liver.
What could go wrong: This is an early-phase 3 trial, so results may not confirm benefit. The experimental drug may cause side effects or not improve outcomes compared to existing therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC ADENOCARCINOMA AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.